Gustave Roussy, Cancer Campus, Grand Paris
289
61
76
108
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
12.1%
35 terminated/withdrawn out of 289 trials
75.5%
-11.0% vs industry average
22%
63 trials in Phase 3/4
3%
3 of 108 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (289)
Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients
Role: collaborator
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
Role: lead
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Role: lead
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Role: collaborator
Long Term Neurocognitive Effects of Low-dose Radiation in the Brain: Study of 150 Patients in the French Hemangioma Cohort
Role: collaborator
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
Role: lead
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Role: lead
Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma
Role: collaborator
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Role: lead
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
Role: lead
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Role: lead
Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling
Role: lead
Optimized Angiomammography and Comparison With Standard Angiomammography
Role: lead
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
Role: lead
Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors
Role: lead
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
Role: lead
Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma
Role: lead
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Role: lead
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
Role: lead
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Role: lead